Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism

OMAHA, Neb. (February 24, 2010) – Transgenomic, Inc. (OTC/BB: TBIO) announced today that it has
licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable
Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in
children who have older siblings diagnosed with an autism spectrum disorder. Under the agreement
Transgenomic will develop the test in the Company’s CAP-accredited and CLIA-certified laboratory, and
anticipates launching the new test in the second quarter of 2010. Financial terms of the agreement were
not disclosed.

“We are pleased to have the opportunity to develop and offer a genetic test to clinicians and parents that
will assist in the evaluation of children who are thought to be at high risk of being autistic,” stated Craig
Tuttle, president and chief executive officer of Transgenomic. “We believe that the use of this test in
conjunction with standard diagnostic tools will allow for the earlier diagnosis of autism, and importantly,
the more timely initiation of treatment plans for these children. We look forward to adding this
proprietary test to our growing commercial offerings.”

Autism is a developmental disorder that causes significant social, communication and behavioral
challenges in children. The Centers for Disease Control and Prevention estimates that one in 110 children
in the U.S. has an autism-related disorder, and that the incidence of autism is up 57 percent from 2002 to
2006. Even though parents typically express concerns about their child's developmental progress before
the age of three, the average age of diagnoses is not until 53 months. Early intervention has been shown
to be effective in improving a child’s ability to develop into a competent adult. Children with a sibling
who has been diagnosed with autism are at a significantly greater risk of developing the disorder.
“IntegraGen is excited about the opportunity for our technology to be commercialized by Transgenomic,”
said Dr. Bernard Courtieu, chief executive officer of IntegraGen. “We will continue our gene discovery
efforts to further our understanding of autism while focusing on other diseases where molecular tests may
help with patient diagnosis and disease management.”

About IntegraGen
IntegraGen (www.integragen.com) is a Biotechnology Company dedicated to gene discovery which
allows for the development of molecular diagnostics products and services that provide clinicians with
new tools to personalize diagnosis, treatment, and therapy. IntegraGen is focused on the prevention and
proactive management of complex debilitating diseases, and dedicated to addressing the needs of patients,
clinicians, and advocacy groups. IntegraGen’s Genetic Services Business also provides state of the art
Genotyping Services to the research community. With discovery and intellectual property focused on
Autism, Oncology and Metabolism, IntegraGen’s Core Strategy is to deliver a portfolio of high-value
molecular diagnostic products and services that drive personalized healthcare solutions for complex
diseases.

About Transgenomic, Inc.
Transgenomic, Inc. (www.transgenomic.com ) is a global biotechnology company specializing in high
sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation
detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics
analyses. Its product offerings include the WAVE® Systems and associated consumables specifically
designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and
purification. With broad applicability to genetic research, over 1,475 systems have been shipped to
customers in more than 30 countries. The SURVEYOR® Mutation Detection Kits and SURVEYOR
Check-It Kit provide reagents and protocols for high sensitivity detection of mutations in DNA. In
addition, HANABI automated chromosome harvesting systems improve laboratory productivity with
consistent quality compared with manual methods for cytogenetic analyses. Service offerings include the
Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in
molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular
Pathology and Inherited Diseases. Transgenomic Pharmacogenomics Services is a CRO for
pharmacogenomic, translational research and clinical trials.

Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” of Transgenomic within
the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown
risks, uncertainties and other factors that may cause actual results to be materially different from any
future results, performance or achievements expressed or implied by such statements. Forward-looking
statements include, but are not limited to, those with respect to management’s current views and estimates
of future economic circumstances, industry conditions, company performance and financial results,
including the ability of the Company to grow its involvement in the diagnostic products and services
markets. The known risks, uncertainties and other factors affecting these forward-looking statements are
described from time to time in Transgenomic’s filings with the Securities and Exchange Commission.
Any change in such factors, risks and uncertainties may cause the actual results, events and performance
to differ materially from those referred to in such statements. Accordingly, the Company claims the
protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995 with respect to all statements contained in this press release. All information in this
press release is as of the date of the release and Transgenomic does not undertake any duty to update this
information, including any forward-looking statements, unless required by law.

For more information regarding this press release, please contact Transgenomic at:

Phone: 402-452-5437; Fax: 402-452-5461; Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it